Pharmaceutical Economics & Health Policy
This section features articles on economic evaluation, health outcomes, and policy issues related to drug therapy. Published manuscripts include review articles, original contributions, brief reports, and commentaries. Because of the rapid publication process, time-sensitive topics are of particular interest. All manuscripts are peer reviewed for clinical relevance, technical accuracy, clarity, and objectivity. Specific research topics that are being targeted for publication include, but are not limited to:
Economic Evaluation
- Cost-effectiveness analyses and cost-benefit analyses of pharmaceuticals and health technologies
- Validations and applications of health economic models
- Methodologic advances and applications (eg, probabilistic sensitivity analysis; budget impact analysis)
- Impact of compliance on cost-effectiveness
- Critical assessments of economic evaluations within therapeutic classes
- Claims data analyses: applied health services research that examines determinants of health care costs
Health Outcomes and Comparative Effectiveness
- Health technology assessments (HTAs)
- Development/validation of health outcomes assessment tools in the evaluation of pharmaceutical interventions
- Longitudinal analyses of health-related quality-of-life (HRQoL) assessments in pharmaceutical trials
- Studies addressing patient-reported outcomes (PROs)
- Comparative effectiveness reviews
Health Policy and Evidence-Based Medicine
- Evaluations of utilization-management strategies (eg, formularies, tier copays)
- Evaluations of clinical evidence for disease state management
- Evaluations of the impact of direct-to-consumer advertising
- Studies that provide insight into physician prescribing behaviors
- Health disparities research and program evaluations of community-based interventions
- Evaluations of compliance programs or comparisons of compliance profiles across drugs
